gene variants and thiopurine-induced leukopenia in patients with inflammatory bowel disease

Thiopurine has been used to maintain remission and to reduce antidrug antibody formation in monoclonal antibody therapy in patients with inflammatory bowel disease (IBD). The use of thiopurine is limited by side effects such as leukopenia. Thiopurine S-methyltransferase (TPMT) variants are associate...

Full description

Bibliographic Details
Main Author: Katsuyoshi Matsuoka
Format: Article
Language:English
Published: Korean Association for the Study of Intestinal Diseases 2020-07-01
Series:Intestinal Research
Subjects:
Online Access:http://www.irjournal.org/upload/pdf/ir-2020-00002.pdf
_version_ 1818519515159330816
author Katsuyoshi Matsuoka
author_facet Katsuyoshi Matsuoka
author_sort Katsuyoshi Matsuoka
collection DOAJ
description Thiopurine has been used to maintain remission and to reduce antidrug antibody formation in monoclonal antibody therapy in patients with inflammatory bowel disease (IBD). The use of thiopurine is limited by side effects such as leukopenia. Thiopurine S-methyltransferase (TPMT) variants are associated with thiopurine-induced leukopenia in Westerners, but the frequency of the risk alleles is low in Asians. Recently, a variant in the nudix hydrolase 15 (NUDT15) gene (R139C, c.415C > T) was reported to be associated with early severe leukopenia in Asians. NUDT15 is an enzyme that converts 6-thio-(deoxy)guanosine triphosphate (6-T(d)GTP) to 6-thio-(deoxy)guanosine monophosphate (6-T(d)GMTP). The R139C variant impairs the stability of the protein and increases incorporation of 6-TGTP and 6-TdGTP into RNA and DNA, respectively, resulting in leukopenia. The frequency of C/C, C/T, and T/T are approximately 80%, 20%, and 1%, respectively in East Asians. Early leukopenia occurred in less than 3% of patients with C/C and in around 20% of those with C/T, whereas it occurred in almost all patients with T/T. Patients homozygous for this variant also develop severe hair loss. The measurement of NUDT15 R139C can increase the safety of thiopurine dramatically and is a successful example of personalized medicine in the field of IBD.
first_indexed 2024-12-11T01:25:13Z
format Article
id doaj.art-f41a06260d794c4b8cb0dbe53ab88803
institution Directory Open Access Journal
issn 1598-9100
2288-1956
language English
last_indexed 2024-12-11T01:25:13Z
publishDate 2020-07-01
publisher Korean Association for the Study of Intestinal Diseases
record_format Article
series Intestinal Research
spelling doaj.art-f41a06260d794c4b8cb0dbe53ab888032022-12-22T01:25:35ZengKorean Association for the Study of Intestinal DiseasesIntestinal Research1598-91002288-19562020-07-0118327528110.5217/ir.2020.00002847gene variants and thiopurine-induced leukopenia in patients with inflammatory bowel diseaseKatsuyoshi MatsuokaThiopurine has been used to maintain remission and to reduce antidrug antibody formation in monoclonal antibody therapy in patients with inflammatory bowel disease (IBD). The use of thiopurine is limited by side effects such as leukopenia. Thiopurine S-methyltransferase (TPMT) variants are associated with thiopurine-induced leukopenia in Westerners, but the frequency of the risk alleles is low in Asians. Recently, a variant in the nudix hydrolase 15 (NUDT15) gene (R139C, c.415C > T) was reported to be associated with early severe leukopenia in Asians. NUDT15 is an enzyme that converts 6-thio-(deoxy)guanosine triphosphate (6-T(d)GTP) to 6-thio-(deoxy)guanosine monophosphate (6-T(d)GMTP). The R139C variant impairs the stability of the protein and increases incorporation of 6-TGTP and 6-TdGTP into RNA and DNA, respectively, resulting in leukopenia. The frequency of C/C, C/T, and T/T are approximately 80%, 20%, and 1%, respectively in East Asians. Early leukopenia occurred in less than 3% of patients with C/C and in around 20% of those with C/T, whereas it occurred in almost all patients with T/T. Patients homozygous for this variant also develop severe hair loss. The measurement of NUDT15 R139C can increase the safety of thiopurine dramatically and is a successful example of personalized medicine in the field of IBD.http://www.irjournal.org/upload/pdf/ir-2020-00002.pdfnudt15thiopurineazathioprine6-mercaptopurine
spellingShingle Katsuyoshi Matsuoka
gene variants and thiopurine-induced leukopenia in patients with inflammatory bowel disease
Intestinal Research
nudt15
thiopurine
azathioprine
6-mercaptopurine
title gene variants and thiopurine-induced leukopenia in patients with inflammatory bowel disease
title_full gene variants and thiopurine-induced leukopenia in patients with inflammatory bowel disease
title_fullStr gene variants and thiopurine-induced leukopenia in patients with inflammatory bowel disease
title_full_unstemmed gene variants and thiopurine-induced leukopenia in patients with inflammatory bowel disease
title_short gene variants and thiopurine-induced leukopenia in patients with inflammatory bowel disease
title_sort gene variants and thiopurine induced leukopenia in patients with inflammatory bowel disease
topic nudt15
thiopurine
azathioprine
6-mercaptopurine
url http://www.irjournal.org/upload/pdf/ir-2020-00002.pdf
work_keys_str_mv AT katsuyoshimatsuoka genevariantsandthiopurineinducedleukopeniainpatientswithinflammatoryboweldisease